Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Respiratory Medicine
- Vol. 146, 66-70
- https://doi.org/10.1016/j.rmed.2018.11.021
Abstract
No abstract availableKeywords
Funding Information
- National Hospital Organization fiduciary funds
- Grant-in-Aid for Young Scientists
- KAKENHI
- Japan Society for the Promotion of Science, Japan (17K16067)
This publication has 14 references indexed in Scilit:
- CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockadeMolecular Medicine Reports, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapyWorld Journal of Hepatology, 2015
- Opportunistic infections in patients treated with immunotherapy for cancerJournal for ImmunoTherapy of Cancer, 2014
- PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patientsMolecular Immunology, 2008
- PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature, 2006
- Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretroviralsThe Lancet Infectious Diseases, 2005